Screener
Monte Rosa Therapeutics, Inc. GLUE Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s current ratio?
- Monte Rosa Therapeutics, Inc. (GLUE) reported current ratio of 10.6× in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s current ratio changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s current ratio increased by 47.9% year-over-year, from 7.2× to 10.6×.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s current ratio?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s current ratio has grown at a 32.7% compound annual growth rate (CAGR), from 1.5× to 6.1×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Monte Rosa Therapeutics, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude